Bo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bo Li has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Weiliang Zhu
CAS Key Laboratory of Receptor Research; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
30 shared publications - Zhijian Xu
State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica
22 shared publications - Jumei Shi
Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
13 shared publications Yong Zhang
State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
12 shared publicationsKaixian Chen
University of Chinese Academy of Sciences Beijing 100049 China
11 shared publicationsYitian Zhao
State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China; Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
9 shared publications
Latest Publications
- 24 June 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 418, 111620
Thiazole-fused thiazoliniums with ketone warheads as covalent inhibitors targeting Cys44 of SARS-CoV-2 3CLpro
- 24 June 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 418, 111620
Thiazole-fused thiazoliniums with ketone warheads as covalent inhibitors targeting Cys44 of SARS-CoV-2 3CLpro
- Open Access
- 25 December 2024
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2413122
Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation
Promoting tumor cell senescence arrests the cell cycle of tumor cells and activates the immune system to eliminate these senescent cells, thereby suppressing tumor growth. Nevertheless, PD‐L1 positive senescent tumor cells resist immune clearance and possess the ability to secret various cytokines and inflammatory factors that stimulate the growth of tumor cells. Consequently, drugs capable of both triggering senescence in tumor cells and concurrently diminishing the expression of PD‐L1 to counteract immune evasion are urgently needed. Here, a berberine derivative B68 is developed, which specifically induces tumor cell senescence by targeting BMI1. B68 also involves the degradation of PD‐L1 by targeting CSN5, thereby disrupting the immunosuppressive PD‐1/PD‐L1 interaction and enabling rapid clearance of senescent tumor cells. This approach simultaneously inhibits tumor progression and activates T cell immunity, as evidenced by the robust antitumor response following B68‐induced immunization of senescent cancer cells. Moreover, the synergistic effect of B68 with anti‐CTLA4 therapy further enhances antitumor immunity, and its ability to induce senescence in cancer cells triggers a strong protective response by dendritic and CD8+ T cells. These findings provide a scientific basis for developing a new tumor treatment strategy based on senescence induction and lay the foundation for further preclinical research.
- 25 December 2024
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2413122
Open AccessBerberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation
Promoting tumor cell senescence arrests the cell cycle of tumor cells and activates the immune system to eliminate these senescent cells, thereby suppressing tumor growth. Nevertheless, PD‐L1 positive senescent tumor cells resist immune clearance and possess the ability to secret various cytokines and inflammatory factors that stimulate the growth of tumor cells. Consequently, drugs capable of both triggering senescence in tumor cells and concurrently diminishing the expression of PD‐L1 to counteract immune evasion are urgently needed. Here, a berberine derivative B68 is developed, which specifically induces tumor cell senescence by targeting BMI1. B68 also involves the degradation of PD‐L1 by targeting CSN5, thereby disrupting the immunosuppressive PD‐1/PD‐L1 interaction and enabling rapid clearance of senescent tumor cells. This approach simultaneously inhibits tumor progression and activates T cell immunity, as evidenced by the robust antitumor response following B68‐induced immunization of senescent cancer cells. Moreover, the synergistic effect of B68 with anti‐CTLA4 therapy further enhances antitumor immunity, and its ability to induce senescence in cancer cells triggers a strong protective response by dendritic and CD8+ T cells. These findings provide a scientific basis for developing a new tumor treatment strategy based on senescence induction and lay the foundation for further preclinical research.
- Open Access
- 9 September 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-10
Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
Multi-functional cysteine-targeting covalent warheads possess significant therapeutic potential in medicinal chemistry and chemical biology. Herein, we present novel unsaturated and asymmetric ketone (oxazolinosene) scaffolds that selectively conjugate cysteine residues of peptides and bovine serum albumin under normal physiological conditions. This unsaturated saccharide depletes GSH in NCI-H1299 cells, leading to anti-tumor effects in vitro. The acetyl group of the ketal moiety on the saccharide ring can be converted to other carboxylic acids in a one-pot synthesis. In this way, the loaded acid can be click-released during cysteine conjugation, making the oxazolinosene a potential multifunctional therapeutic agent. The reaction kinetic model for oxazolinosene conjugation to GSH is well established and was used to evaluate oxazolinosene reactivity. The aforementioned oxazolinosenes were stereoselectively synthesized via a one-step reaction of nitriles with saccharides and conveniently converted into a series of α, β-unsaturated ketone N-glycosides as prevalent synthetic building blocks. The reaction mechanisms of oxazolinosene synthesis were investigated through calculations and validated with control experiments. Overall, these oxazolinosenes can be easily synthesized and developed as cysteine-targeted covalent warheads carrying useful click-releasing groups.
- 9 September 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-10
Open AccessDevelopment of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
Multi-functional cysteine-targeting covalent warheads possess significant therapeutic potential in medicinal chemistry and chemical biology. Herein, we present novel unsaturated and asymmetric ketone (oxazolinosene) scaffolds that selectively conjugate cysteine residues of peptides and bovine serum albumin under normal physiological conditions. This unsaturated saccharide depletes GSH in NCI-H1299 cells, leading to anti-tumor effects in vitro. The acetyl group of the ketal moiety on the saccharide ring can be converted to other carboxylic acids in a one-pot synthesis. In this way, the loaded acid can be click-released during cysteine conjugation, making the oxazolinosene a potential multifunctional therapeutic agent. The reaction kinetic model for oxazolinosene conjugation to GSH is well established and was used to evaluate oxazolinosene reactivity. The aforementioned oxazolinosenes were stereoselectively synthesized via a one-step reaction of nitriles with saccharides and conveniently converted into a series of α, β-unsaturated ketone N-glycosides as prevalent synthetic building blocks. The reaction mechanisms of oxazolinosene synthesis were investigated through calculations and validated with control experiments. Overall, these oxazolinosenes can be easily synthesized and developed as cysteine-targeted covalent warheads carrying useful click-releasing groups.
- 22 July 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 111, 117843
Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma
- 22 July 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 111, 117843
Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma
- 28 December 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 127, 111446
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
- 28 December 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 127, 111446
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
- 12 December 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 98, 129590
Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
- 12 December 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 98, 129590
Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
- 30 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt A) , 111139
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells
- 30 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt A) , 111139
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells
- 6 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 95, 129435
Design, synthesis and biological evaluation of chalcone derivatives as potent and orally active hCYP3A4 inhibitors
- 6 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 95, 129435
Design, synthesis and biological evaluation of chalcone derivatives as potent and orally active hCYP3A4 inhibitors
- 11 July 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 91, 117413
Design, synthesis and biological evaluation of salicylanilides as novel allosteric inhibitors of human pancreatic lipase
- 11 July 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 91, 117413
Design, synthesis and biological evaluation of salicylanilides as novel allosteric inhibitors of human pancreatic lipase